Intellectual Property Estate
Evox has created a comprehensive intellectual property portfolio encompassing key aspects of EV-based drug delivery technology. Coupled with tailored targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across several disease areas, using a wide array of therapeutic modalities.
Key aspects of Evox’s intellectual property portfolio includes:
- Exosomes for delivery of nucleic acid-based agents
- Exosomes for delivery of protein therapeutics, including antibodies, antibody fragments, and receptors
- Targeting of exosomes to tissues and organs of interest
- Exosomes for small molecule delivery